Seven Fleet Capital Management LP Takes $633,000 Position in United Therapeutics Corporation $UTHR

Seven Fleet Capital Management LP acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 130,000 shares of the biotechnology company’s stock, valued at approximately $633,000.

Other hedge funds have also bought and sold shares of the company. Torren Management LLC acquired a new position in United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $31,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,540,358.40. This trade represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 644,468 shares of company stock worth $364,004,497 over the last quarter. 8.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Oppenheimer lifted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Price Performance

Shares of UTHR opened at $536.59 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company has a market cap of $22.78 billion, a PE ratio of 19.81, a P/E/G ratio of 1.80 and a beta of 0.57. The stock has a 50-day moving average of $565.37 and a 200-day moving average of $523.32.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company posted $6.63 earnings per share. Analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.